

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Brain and Cerebral Meninges

C70.0, C71.0-C71.9

C70.0 Cerebral meninges

C71.0 Cerebrum

C71.1 Frontal lobe

C71.2 Temporal lobe

C71.3 Parietal lobe

C71.4 Occipital lobe

C71.5 Ventricle, NOS

C71.6 Cerebellum, NOS

C71.7 Brain stem

C71.8 Overlapping lesion of brain

C71.9 Brain, NOS

Note 1: This scheme is compatible with the AJCC fourth edition scheme TNM for brain. The AJCC opted not to recommend a TNM scheme in the sixth or seventh editions.

Note 2: AJCC does not define TNM staging for this site.

CS Tumor Size	CS Site-Specific Factor 1 WHO Grade Classification	The following tables are available at the collaborative staging website: Histology Inclusion Table AJCC 7th ed. Histology Exclusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage
CS Extension	CS Site-Specific Factor 2 Proliferative Fraction-Ki-67/MIB-1	
CS Tumor Size/Ext Eval	CS Site-Specific Factor 3 Function neurological status- The Karnofsky Performance Score/Scale	
CS Lymph Nodes	CS Site-Specific Factor 4 MGMT - Methylation of MGMT	
CS Lymph Nodes Eval	CS Site-Specific Factor 5 Chromosome 1p: Loss of Heterozygosity (LOH)	
Reg LN Pos	CS Site-Specific Factor 6 Chromosome 19q: Loss of Heterozygosity (LOH)	
Reg LN Exam	CS Site-Specific Factor 7 Surgical Resection	
CS Mets at DX	CS Site-Specific Factor 8 Focus of Primary Tumor	
CS Mets Eval	CS Site-Specific Factor 9	
	CS Site-Specific Factor 10	
	CS Site-Specific Factor 11	
	CS Site-Specific Factor 12	
	CS Site-Specific Factor 13	
	CS Site-Specific Factor 14	
	CS Site-Specific Factor 15	
	CS Site-Specific Factor 16	
	CS Site-Specific Factor 17	
	CS Site-Specific Factor 18	
	CS Site-Specific Factor 19	
	CS Site-Specific Factor 20	
	CS Site-Specific Factor 21	
	CS Site-Specific Factor 22	
	CS Site-Specific Factor 23	
	CS Site-Specific Factor 24	
	CS Site-Specific Factor 25	

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Brain and Cerebral Meninges

CS Tumor Size (Revised: 10/07/2009)

Code	Description
000	No mass/tumor found
001-988	001 - 988 millimeters (code exact size in millimeters)
989	989 millimeters or larger
990	Microscopic focus or foci only, no size of focus given
991	Described as "less than 1 cm"
992	Described as "less than 2 cm," or "greater than 1 cm," or "between 1 cm and 2 cm"
993	Described as "less than 3 cm," or "greater than 2 cm," or "between 2 cm and 3 cm"
994	Described as "less than 4 cm," or "greater than 3 cm," or "between 3 cm and 4 cm"
995	Described as "less than 5 cm," or "greater than 4 cm," or "between 4 cm and 5 cm"
999	Unknown; size not stated Not documented in patient record

Brain and Cerebral Meninges

CS Extension (Revised: 11/25/2009)

Note 1: C71.0 is SUPRAtentorial, except the following subsites coded to C71.0 are INFRAtentorial: hypothalamus, pallium, thalamus. C71.1-C71.5 are SUPRAtentorial. C71.6-C71.7 are INFRAtentorial. The following subsites coded to C71.8 are SUPRAtentorial: corpus callosum, tapetum. The following sites coded to C71.9 are SUPRAtentorial: anterior cranial fossa, middle cranial fossa, suprasellar. The following subsites coded to C71.9 are INFRAtentorial: posterior cranial fossa.

Note 2: Tumors affecting the central nervous system rarely develop extraneural metastases, probably because of inherent biologic characteristics of these tumors, and also because the brain does not have a well-developed drainage system. Tumors do spread through cerebrospinal fluid (CSF) pathways, and such spread has a major impact on survival. It is important to differentiate between extraneural metastasis and metastasis within the CNS and CSF pathways and record distant spread in the Mets at DX table.

Code	Description	TNM 7	TNM 6	SS77	SS2000
050	Benign or borderline brain tumors	NA	NA	NA	NA
100	Supratentorial tumor confined to: CEREBRAL HEMISPHERE (cerebrum) or MENINGES of CEREBRAL HEMI-SPHERE on one side: Frontal lobe Occipital lobe Parietal lobe Temporal lobe	NA	NA	L	L

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7	TNM 6	SS77	SS2000
110	Infratentorial tumor confined to: CEREBELLUM or MENINGES of CEREBELLUM on one side: Vermis: Lateral lobes Median lobe of cerebellum	NA	NA	L	L
120	Infratentorial tumor confined to: BRAIN STEM or MENINGES of BRAIN STEM on one side: Medulla oblongata Midbrain (mesencephalon) Pons Hypothalamus Thalamus	NA	NA	L	L
150	Confined to brain, NOS Confined to meninges, NOS	NA	NA	L	L
200	Infratentorial tumor: Both cerebellum and brain stem involved with tumor on one side	NA	NA	L	L
300	Confined to ventricles Tumor invades or encroaches upon ventricular system	NA	NA	L	L
400	Tumor crosses the midline Tumor involves contralateral hemisphere Tumor involves corpus callosum (including splenium)	NA	NA	RNOS	RNOS
500	Supratentorial tumor extends infratentorially to involve cerebellum or brain stem	NA	NA	RNOS	RNOS
510	Infratentorial tumor extends supratentorially to involve cerebrum (cerebral hemisphere)	NA	NA	RNOS	RNOS
600	Tumor invades: Bone (skull) Major blood vessel(s) Meninges (dura) Nerves, NOS Cranial nerves Spinal cord/canal	NA	NA	RNOS	RNOS
700	Circulating cells in cerebral spinal fluid (CSF) Nasal cavity Nasopharynx Posterior pharynx Outside central nervous system (CNS)	NA	NA	D	D
750	Extension to: Nasal cavity Nasopharynx Posterior pharynx	NA	NA	D	D

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7	TNM 6	SS77	SS2000
800	Further contiguous extension	NA	NA	D	D
950	No evidence of primary tumor	NA	NA	U	U
999	Unknown extension Primary tumor cannot be assessed Not documented in patient record	NA	NA	U	U

Brain and Cerebral Meninges

CS Tumor Size/Ext Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Brain and Cerebral Meninges

CS Lymph Nodes (Revised: 01/13/2010)

Code	Description	TNM 7	TNM 6	SS77	SS2000
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable	ERROR	ERROR	ERROR	ERROR
988	Not applicable: Information not collected for this schema	NA	NA	U	U

Brain and Cerebral Meninges

CS Lymph Nodes Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Brain and Cerebral Meninges

Reg LN Pos (Revised: 06/30/2008)

Code	Description
99	Not applicable

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Brain and Cerebral Meninges

Reg LN Exam (Revised: 06/30/2008)

Code	Description
99	Not applicable

Brain and Cerebral Meninges

CS Mets at DX (Revised: 10/07/2009)

Code	Description	TNM 7	TNM 6	SS77	SS2000
00	No; none	NA	NA	NONE	NONE
10	Distant metastases	NA	NA	D	D
85	"Drop" metastases	NA	NA	D	D
99	Unknown Distant metastasis cannot be assessed Not documented in patient record	NA	NA	U	U

Brain and Cerebral Meninges

CS Mets Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Brain and Cerebral Meninges

CS Site-Specific Factor 1 WHO Grade Classification (Revised: 10/07/2009)

Note: Code the WHO Grade Classification as documented in the medical record.

Code	Description
010	Grade I
020	Grade II
030	Grade III
040	Grade IV
999	Clinically diagnosed/grade unknown Not documented in medical record Grade unknown, NOS

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Brain and Cerebral Meninges

CS Site-Specific Factor 2 Proliferative Fraction- Ki-67/MIB-1 (Revised: 12/23/2009)

Note 1: Ki-67 and MIB-1 are labeling indexes used as a complementary method to differentiate better and worse prognostic groups of certain brain tumors. They evaluate the cell kinetics in brain tumors. Code the labeling index fraction percentage using Ki-67 or MIB-1 (monoclonal antibody) when it is available on the final diagnosis of the pathology report of the primary brain tumor.

Note 2: Record the Labeling Index (LI) percentage as documented by the pathologist as an exact number (001-100). For instance, if the LI level is recorded by the pathologist as 15%, assign code 015. If percentage is documented as 13.7% round up to 14% and assign code 014. If percentage is documented as 13.2%, round down to 13% and assign code 013.

Code	Description
001-100	1-100% (code exact Labeling Index percentage) Examples: 001 = 1% 010 = 10% 014 = 13.7% 055 = 55.2%
200	Labeling Index normal
300	Labeling Index stated as slightly elevated and no percentage provided
400	Labeling Index stated as elevated and no percentage provided
888	OBSOLETE DATA CONVERTED V0200 See code 988. Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Brain and Cerebral Meninges

CS Site-Specific Factor 3 Function neurological status- The Karnofsky Performance Score/Scale (Revised: 01/21/2010)

Note 1: The Karnofsky Performance Scale (KPS) Index allows patients to be classified as to their functional impairment. This can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. The lower the Karnofsky score, the worse the survival for most serious illnesses.

Note 2: Record the KPS using information in the patient's record or record the KPS as documented in the patient's record by the physician. 100 Normal no complaints; no evidence of disease 90 Able to carry on normal activity; minor signs or symptoms of disease 80 Normal activity with effort; some signs or symptoms of disease 70 Cares for self; unable to carry on normal activity normal activity or to do active work 60 Requires occasional assistance, but is able to care for most of his personal needs 50 Requires considerable assistance and frequent medical care 40 Disabled; requires special care and assistance 30 Severely disables; hospital admission is indicated although death not imminent 20 Very; hospital admission necessary; active supportive treatment necessary 10 Moribund; fatal processes progressing rapidly 0 Dead

Code	Description
000-100	Karnofsky Performance Score (KPS) KPS Score 40 = Code 040
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
999	Unknown Not documented in patient record

Brain and Cerebral Meninges

CS Site-Specific Factor 4 MGMT - Methylation of MGMT (Revised: 01/17/2010)

Note 1:

MGMT (O6-methylguanine-methyltransferase) is an enzyme in cells that repairs DNA. DNA repair is undesirable in tumors, because they may be able to overcome the DNA damage done by chemotherapy. With methylation, less MGMT enzyme is produced, which may lead to prolonged survival compared to unmethylated MGMT.

Note 2: Code the methylation status of the MGMT gene (also termed MGMT promoter) as stated in the medical record. A positive test result may be termed "methylated," "hypermethylated," or "high." A negative result may be termed "unmethylated" or "low." This molecular test is not part of a routine pathology report.

Code	Description
010	Yes - Methylated Hypermethylated High levels
020	No - Unmethylated Low levels

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
998	No histologic examination of primary site
999	Unknown Not documented in patient record

Brain and Cerebral Meninges

CS Site-Specific Factor 5 Chromosome 1p: Loss of Heterozygosity (LOH) (Revised: 01/21/2010)

Note 1: This is a special molecular diagnostic test performed on tumor tissue to identify loss of genetic material normally found on the short arm of one of the patient's two copies of chromosome 1. A normal cell will contain two complete copies of each chromosome, one from each parent, and this normal state is termed heterozygous. Loss of heterozygosity (LOH) is an abnormal state reflecting damage to the chromosome.

Note 2: Other terms for loss of heterozygosity include gene deletion and allelic loss.

Note 3: For brain tumors, tests for LOH of chromosomes 1p and 19q may be performed at the same time and reported on a single report. See also Site-Specific Factor 6.

Code	Description
010	Test positive for loss of heterozygosity
020	Test negative for loss of heterozygosity
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Brain and Cerebral Meninges

CS Site-Specific Factor 6 Chromosome 19q: Loss of Heterozygosity (LOH) (Revised: 01/17/2010)

Note 1: This is a special molecular diagnostic test performed on tumor tissue to identify loss of genetic material normally found on the long arm of one of the patient's two copies of chromosome 19. A normal cell will contain two complete copies of each chromosome, one from each parent, and this normal state is termed heterozygous. Loss of heterozygosity (LOH) is an abnormal state reflecting damage to the chromosome.

Note 2: Other terms for loss of heterozygosity include gene deletion and allelic loss.

Note 3: For brain tumors, tests for LOH of chromosomes 1p and 19q may be performed at the same time and reported on a single report. See also Site-Specific Factor 5.

Code	Description
010	Test positive for loss of heterozygosity
020	Test negative for loss of heterozygosity
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

Brain and Cerebral Meninges

CS Site-Specific Factor 7 Surgical Resection (Revised: 01/21/2010)

Note 1: Record the details of the surgical resection here even if previously recorded within abstract.

Note 2: If case was clinically diagnosed and there was no surgical resection, code 000.

Note 3: Do not code laminectomies for spinal cord primaries.

Note 4: Do not record stereotactic radiosurgery as tumor destruction. It should be recorded in the radiation treatment items.

Code	Description
000	None; no surgery of primary site; autopsy ONLY
010	Tumor destruction, NOS No specimen sent to pathology from surgical event 10.
020	Local excision (biopsy) of tumor, lesion or mass
021	Subtotal resection of tumor, lesion or mass of brain
022	Resection of tumor of spinal cord or nerve
030	Radical, total, gross resection of tumor, lesion or mass in brain Less than half of lobe involved with tumor for 21 and 30. Specimen sent to pathology from surgical event 20, 21, 22

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
040	Partial resection of lobe of brain
055	Gross total resection of lobe of brain (lobectomy) Tumor involves more than half of lobe for 40, 55; not used for nerve or spinal cord primary.
090	Surgery, NOS
988	Not applicable: Information not collected for this case
999	Unknown if surgery performed; death certificate ONLY Not documented in patient record

Brain and Cerebral Meninges

CS Site-Specific Factor 8 Focus of Primary Tumor (Revised: 01/21/2010)

Note 1: Record tumor focus at initial diagnosis on the resectable and unresectable cases. Unresectable cases can be determined using information recorded in the medical record (radiological imaging studies or managing physician documentation).

Note 2: Use code 001 when tumor is described as unifocal; arising from or occurring in a single focus or location.

Note 3: Use code 002 when tumor described as multifocal without measurement of foci, or when multiple foci of tumor are measured.

Code	Description
001	Unifocal/Solitary tumor
002	Multifocal tumor Tumor described as multifocal or multicentric, multiplicity counter > 01 or 99
988	Not applicable: Information not collected for this case
999	Unknown Not documented in patient record

Brain and Cerebral Meninges

CS Site-Specific Factor 9 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 10 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Brain and Cerebral Meninges

CS Site-Specific Factor 11 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 12 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 13 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 14 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 15 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 16 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 17 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Brain and Cerebral Meninges

CS Site-Specific Factor 18 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 19 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 20 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 21 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 22 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 23 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Brain and Cerebral Meninges

CS Site-Specific Factor 24 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Brain and Cerebral Meninges

CS Site-Specific Factor 25 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other Parts of Central Nervous System

C70.1, C70.9, C72.0-C72.5, C72.8-C72.9

- C70.1 Spinal meninges
- C70.9 Meninges, NOS
- C72.0 Spinal cord
- C72.1 Cauda equina
- C72.2 Olfactory nerve
- C72.3 Optic nerve
- C72.4 Acoustic nerve
- C72.5 Cranial nerve, NOS
- C72.8 Overlapping lesion of brain and central nervous system
- C72.9 Nervous system, NOS

Note: This schema is compatible with the AJCC fourth edition TNM for spinal cord. AJCC does not define TNM staging for this site in the sixth or seventh editions.

<ul style="list-style-type: none"> CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval 	<ul style="list-style-type: none"> CS Site-Specific Factor 1 WHO Grade Classification CS Site-Specific Factor 2 Proliferative Fraction-Ki-67/MIB-1 CS Site-Specific Factor 3 Function neurological status- The Karnofsky Performance Score/Scale CS Site-Specific Factor 4 MGMT - Methylation of MGMT CS Site-Specific Factor 5 Chromosome 1p: Loss of Heterozygosity (LOH) CS Site-Specific Factor 6 Chromosome 19q: Loss of Heterozygosity (LOH) CS Site-Specific Factor 7 Surgical Resection CS Site-Specific Factor 8 Focus of Primary Tumor CS Site-Specific Factor 9 CS Site-Specific Factor 10 CS Site-Specific Factor 11 CS Site-Specific Factor 12 CS Site-Specific Factor 13 CS Site-Specific Factor 14 CS Site-Specific Factor 15 CS Site-Specific Factor 16 CS Site-Specific Factor 17 CS Site-Specific Factor 18 CS Site-Specific Factor 19 CS Site-Specific Factor 20 CS Site-Specific Factor 21 CS Site-Specific Factor 22 CS Site-Specific Factor 23 CS Site-Specific Factor 24 CS Site-Specific Factor 25 	<p>The following tables are available at the collaborative staging website:</p> <ul style="list-style-type: none"> Histology Inclusion Table AJCC 7th ed. Histology Exclusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage
--	---	--

Other Parts of Central Nervous System

CS Tumor Size (Revised: 10/07/2009)

Code	Description
000	No mass/tumor found

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
001-988	001 - 988 millimeters (code exact size in millimeters)
989	989 millimeters or larger
990	Microscopic focus or foci only, no size of focus given
991	Described as "less than 1 cm"
992	Described as "less than 2 cm," or "greater than 1 cm," or "between 1 cm and 2 cm"
993	Described as "less than 3 cm," or "greater than 2 cm," or "between 2 cm and 3 cm"
994	Described as "less than 4 cm," or "greater than 3 cm," or "between 3 cm and 4 cm"
995	Described as "less than 5 cm," or "greater than 4 cm," or "between 4 cm and 5 cm"
999	Unknown; size not stated Not documented in patient record

Other Parts of Central Nervous System

CS Extension (Revised: 10/07/2009)

Code	Description	TNM 7	TNM 6	SS77	SS2000
050	Benign or borderline brain and other parts of the CSN tumors	NA	NA	NA	NA
100	Tumor confined to tissue or site of origin	NA	NA	L	L
300	Localized, NOS	NA	NA	L	L
400	Meningeal tumor infiltrates nerve Nerve tumor infiltrates meninges (dura)	NA	NA	RNOS	RNOS
500	Adjacent connective/soft tissue Adjacent muscle	NA	NA	RNOS	RNOS
600	Brain, for cranial nerve tumors Major blood vessel(s) Sphenoid and frontal sinuses (skull)	NA	NA	RNOS	RNOS
700	Brain except for cranial nerve tumors Bone, other than skull Eye	NA	NA	D	D
800	Further contiguous extension	NA	NA	D	D
950	No evidence of primary tumor	NA	NA	U	U
999	Unknown extension Primary tumor cannot be assessed Not documented in patient record	NA	NA	U	U

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other Parts of Central Nervous System

CS Tumor Size/Ext Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Other Parts of Central Nervous System

CS Lymph Nodes (Revised: 01/13/2010)

Code	Description	TNM 7	TNM 6	SS77	SS2000
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable	ERROR	ERROR	ERROR	ERROR
988	Not applicable: Information not collected for this schema	NA	NA	U	U

Other Parts of Central Nervous System

CS Lymph Nodes Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Other Parts of Central Nervous System

Reg LN Pos (Revised: 06/30/2008)

Code	Description
99	Not applicable

Other Parts of Central Nervous System

Reg LN Exam (Revised: 06/30/2008)

Code	Description
99	Not applicable

Other Parts of Central Nervous System

CS Mets at DX (Revised: 11/19/2009)

Code	Description	TNM 7	TNM 6	SS77	SS2000
00	No; none	NA	NA	NONE	NONE

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7	TNM 6	SS77	SS2000
10	Distant lymph node(s), NOS	NA	NA	D	D
40	Distant metastases except distant lymph node(s) (code 10) Carcinomatosis	NA	NA	D	D
50	40 + 10 Other distant metastases plus distant lymph node(s)	NA	NA	D	D
60	Distant metastasis, NOS	NA	NA	D	D
99	Unknown if distant metastasis Distant metastasis cannot be assessed Not documented in patient record	NA	NA	U	U

Other Parts of Central Nervous System

CS Mets Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Other Parts of Central Nervous System

CS Site-Specific Factor 1 WHO Grade Classification (Revised: 10/07/2009)

Note: Code the WHO Grade Classification as documented in the medical record.

Code	Description
010	Grade I
020	Grade II
030	Grade III
040	Grade IV
999	Clinically diagnosed/grade unknown Not documented in medical record Grade unknown, NOS

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other Parts of Central Nervous System

CS Site-Specific Factor 2 Proliferative Fraction- Ki-67/MIB-1 (Revised: 12/23/2009)

Note 1: Ki-67 and MIB-1 are labeling indexes used as a complementary method to differentiate better and worse prognostic groups of certain brain tumors. They evaluate the cell kinetics in brain tumors. Code the labeling index fraction percentage using Ki-67 or MIB-1 (monoclonal antibody) when it is available on the final diagnosis of the pathology report of the primary brain tumor.

Note 2: Record the Labeling Index (LI) percentage as documented by the pathologist as an exact number (001-100). For instance, if the LI level is recorded by the pathologist as 15%, assign code 015. If percentage is documented as 13.7% round up to 14% and assign code 014. If percentage is documented as 13.2%, round down to 13% and assign code 013.

Code	Description
001-100	1-100% (code exact Labeling Index percentage) Examples: 001 = 1% 010 = 10% 014 = 13.7% 055 = 55.2%
200	Labeling Index normal
300	Labeling Index stated as slightly elevated and no percentage provided
400	Labeling Index stated as elevated and no percentage provided
888	OBSOLETE DATA CONVERTED V0200 See code 988. Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other Parts of Central Nervous System

CS Site-Specific Factor 3 Function neurological status- The Karnofsky Performance Score/Scale (Revised: 01/21/2010)

Note 1: The Karnofsky Performance Scale (KPS) Index allows patients to be classified as to their functional impairment. This can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. The lower the Karnofsky score, the worse the survival for most serious illnesses.

Note 2: Record the KPS using information in the patient's record or record the KPS as documented in the patient's record by the physician. 100 Normal no complaints; no evidence of disease 90 Able to carry on normal activity; minor signs or symptoms of disease 80 Normal activity with effort; some signs or symptoms of disease 70 Cares for self; unable to carry on normal activity normal activity or to do active work 60 Requires occasional assistance, but is able to care for most of his personal needs 50 Requires considerable assistance and frequent medical care 40 Disabled; requires special care and assistance 30 Severely disables; hospital admission is indicated although death not imminent 20 Very; hospital admission necessary; active supportive treatment necessary 10 Moribund; fatal processes progressing rapidly 0 Dead

Code	Description
000-100	Karnofsky Performance Score (KPS) KPS Score 40 = Code 040
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
999	Unknown Not documented in patient record

Other Parts of Central Nervous System

CS Site-Specific Factor 4 MGMT - Methylation of MGMT (Revised: 01/17/2010)

Note 1:

MGMT (O6-methylguanine-methyltransferase) is an enzyme in cells that repairs DNA. DNA repair is undesirable in tumors, because they may be able to overcome the DNA damage done by chemotherapy. With methylation, less MGMT enzyme is produced, which may lead to prolonged survival compared to unmethylated MGMT.

Note 2: Code the methylation status of the MGMT gene (also termed MGMT promoter) as stated in the medical record. A positive test result may be termed "methylated," "hypermethylated," or "high." A negative result may be termed "unmethylated" or "low." This molecular test is not part of a routine pathology report.

Code	Description
010	Yes - Methylated Hypermethylated High levels
020	No - Unmethylated Low levels

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
998	No histologic examination of primary site
999	Unknown Not documented in patient record

Other Parts of Central Nervous System

CS Site-Specific Factor 5 Chromosome 1p: Loss of Heterozygosity (LOH) (Revised: 01/21/2010)

Note 1: This is a special molecular diagnostic test performed on tumor tissue to identify loss of genetic material normally found on the short arm of one of the patient's two copies of chromosome 1. A normal cell will contain two complete copies of each chromosome, one from each parent, and this normal state is termed heterozygous. Loss of heterozygosity (LOH) is an abnormal state reflecting damage to the chromosome.

Note 2: Other terms for loss of heterozygosity include gene deletion and allelic loss.

Note 3: For brain tumors, tests for LOH of chromosomes 1p and 19q may be performed at the same time and reported on a single report. See also Site-Specific Factor 6.

Code	Description
010	Test positive for loss of heterozygosity
020	Test negative for loss of heterozygosity
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other Parts of Central Nervous System

CS Site-Specific Factor 6 Chromosome 19q: Loss of Heterozygosity (LOH) (Revised: 01/17/2010)

Note 1: This is a special molecular diagnostic test performed on tumor tissue to identify loss of genetic material normally found on the long arm of one of the patient's two copies of chromosome 19. A normal cell will contain two complete copies of each chromosome, one from each parent, and this normal state is termed heterozygous. Loss of heterozygosity (LOH) is an abnormal state reflecting damage to the chromosome.

Note 2: Other terms for loss of heterozygosity include gene deletion and allelic loss.

Note 3: For brain tumors, tests for LOH of chromosomes 1p and 19q may be performed at the same time and reported on a single report. See also Site-Specific Factor 5.

Code	Description
010	Test positive for loss of heterozygosity
020	Test negative for loss of heterozygosity
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

Other Parts of Central Nervous System

CS Site-Specific Factor 7 Surgical Resection (Revised: 01/21/2010)

Note 1: Record the details of the surgical resection here even if previously recorded within abstract.

Note 2: If case was clinically diagnosed and there was no surgical resection, code 000.

Note 3: Do not code laminectomies for spinal cord primaries.

Note 4: Do not record stereotactic radiosurgery as tumor destruction. It should be recorded in the radiation treatment items.

Code	Description
000	None; no surgery of primary site; autopsy ONLY
010	Tumor destruction, NOS No specimen sent to pathology from surgical event 10.
020	Local excision (biopsy) of tumor, lesion or mass
021	Subtotal resection of tumor, lesion or mass of brain
022	Resection of tumor of spinal cord or nerve
030	Radical, total, gross resection of tumor, lesion or mass in brain Less than half of lobe involved with tumor for 21 and 30. Specimen sent to pathology from surgical event 20, 21, 22

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
040	Partial resection of lobe of brain
055	Gross total resection of lobe of brain (lobectomy) Tumor involves more than half of lobe for 40, 55; not used for nerve or spinal cord primary.
090	Surgery, NOS
988	Not applicable: Information not collected for this case
999	Unknown if surgery performed; death certificate ONLY Not documented in patient record

Other Parts of Central Nervous System

CS Site-Specific Factor 8 Focus of Primary Tumor (Revised: 01/21/2010)

Note 1: Record tumor focus at initial diagnosis on the resectable and unresectable cases. Unresectable cases can be determined using information recorded in the medical record (radiological imaging studies or managing physician documentation).

Note 2: Use code 001 when tumor is described as unifocal; arising from or occurring in a single focus or location.

Note 3: Use code 002 when tumor described as multifocal without measurement of foci, or when multiple foci of tumor are measured.

Code	Description
001	Unifocal/Solitary tumor
002	Multifocal tumor Tumor described as multifocal or multicentric, multiplicity counter > 01 or 99
988	Not applicable: Information not collected for this case
999	Unknown Not documented in patient record

Other Parts of Central Nervous System

CS Site-Specific Factor 9 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 10 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other Parts of Central Nervous System

CS Site-Specific Factor 11 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 12 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 13 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 14 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 15 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 16 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 17 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other Parts of Central Nervous System

CS Site-Specific Factor 18 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 19 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 20 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 21 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 22 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 23 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other Parts of Central Nervous System

CS Site-Specific Factor 24 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other Parts of Central Nervous System

CS Site-Specific Factor 25 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Intracranial Gland

C75.1, C75.2, C75.3

C75.1 Pituitary gland

C75.2 Cranipharyngeal duct

C75.3 Pineal Gland

Note 1: AJCC does not define TNM staging for this schema.

CS Tumor Size	CS Site-Specific Factor 1 WHO Grade Classification	The following tables are available at the collaborative staging website: Histology Inclusion Table AJCC 7th ed. Histology Exclusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage
CS Extension	CS Site-Specific Factor 2 Proliferative Fraction-Ki-67/MIB-1	
CS Tumor Size/Ext Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Lymph Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam	CS Site-Specific Factor 7	
CS Mets at DX	CS Site-Specific Factor 8	
CS Mets Eval	CS Site-Specific Factor 9	
	CS Site-Specific Factor 10	
	CS Site-Specific Factor 11	
	CS Site-Specific Factor 12	
	CS Site-Specific Factor 13	
	CS Site-Specific Factor 14	
	CS Site-Specific Factor 15	
	CS Site-Specific Factor 16	
	CS Site-Specific Factor 17	
	CS Site-Specific Factor 18	
	CS Site-Specific Factor 19	
	CS Site-Specific Factor 20	
	CS Site-Specific Factor 21	
	CS Site-Specific Factor 22	
	CS Site-Specific Factor 23	
	CS Site-Specific Factor 24	
	CS Site-Specific Factor 25	

Intracranial Gland

CS Tumor Size (Revised: 02/03/2010)

Code	Description
000	No mass/tumor found
001-988	001 - 988 millimeters (code exact size in millimeters)
989	989 millimeters or larger
990	Microscopic focus or foci only and no size of focus given
991	Described as "less than 1 cm"
992	Described as "less than 2 cm," or "greater than 1 cm," or "between 1 cm and 2 cm"
993	Described as "less than 3 cm," or "greater than 2 cm," or "between 2 cm and 3 cm"
994	Described as "less than 4 cm," or "greater than 3 cm," or "between 3 cm and 4 cm"

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
995	Described as "less than 5 cm," or "greater than 4 cm," or "between 4 cm and 5 cm"
999	Unknown; size not stated Not documented in patient record

Intracranial Gland

CS Extension (Revised: 12/10/2009)

Code	Description	TNM 7	TNM 6	SS77	SS2000
000	In situ; non-invasive; intraepithelial	NA	NA	IS	IS
050	Benign or borderline tumors	NA	NA	NA	NA
100	Invasive carcinoma confined to gland of origin	NA	NA	L	L
300	Localized, NOS	NA	NA	L	L
400	Adjacent connective tissue (See definition in General Instructions)	NA	NA	RE	RE
600	Adjacent organs/structures	NA	NA	RE	RE
800	Further contiguous extension	NA	NA	D	D
950	No evidence of primary tumor	NA	NA	U	U
999	Unknown extension Primary tumor cannot be assessed Not documented in patient record	NA	NA	U	U

Intracranial Gland

CS Tumor Size/Ext Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Intracranial Gland

CS Lymph Nodes (Revised: 01/19/2010)

Note: Code 988 for Lymph nodes.

Code	Description	TNM 7	TNM 6	SS77	SS2000
000	OBSOLETE DATA RETAINED V0200 None; no regional lymph node involvement	NA	NA	NONE	NONE
100	OBSOLETE DATA RETAINED V0200 Regional lymph nodes Cervical for carotid body and parathyroid only Mediastinal for aortic body and thymus only	NA	NA	RN	RN

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7	TNM 6	SS77	SS2000
800	OBSOLETE DATA RETAINED V0200 Lymph nodes, NOS	NA	NA	RN	RN
988	Not applicable	NA	NA	U	U
999	OBSOLETE DATA RETAINED V0200 Unknown; not stated Regional lymph nodes cannot be assessed Not documented in patient record	NA	NA	U	U

Intracranial Gland

CS Lymph Nodes Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Intracranial Gland

Reg LN Pos (Revised: 12/11/2009)

Note 1: Record this field even if there has been preoperative treatment.

Note 2: Use code 99, not applicable, for the following sites: Pituitary gland (C75.1), Craniopharyngeal duct (C75.2), and Pineal gland (C75.3)

Code	Description
00	All nodes examined negative.
01-89	1 - 89 nodes positive (code exact number of nodes positive)
90	90 or more nodes positive
95	Positive aspiration or core biopsy of lymph node(s)
97	Positive nodes - number unspecified
98	No nodes examined
99	Unknown if nodes are positive; not applicable Not documented in patient record

Intracranial Gland

Reg LN Exam (Revised: 12/11/2009)

Note: Use code 99, not applicable, for the following sites: Pituitary gland (C75.1), Craniopharyngeal duct (C75.2), and Pineal gland (C75.3).

Code	Description
00	No nodes examined
01-89	1 - 89 nodes examined (code exact number of regional lymph nodes examined)

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
90	90 or more nodes examined
95	No regional nodes removed, but aspiration or core biopsy of regional nodes performed
96	Regional lymph node removal documented as sampling and number of nodes unknown/not stated
97	Regional lymph node removal documented as dissection and number of nodes unknown/not stated
98	Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection; nodes examined, but number unknown
99	Unknown if nodes were examined; not applicable or negative Not documented in patient record

Intracranial Gland

CS Mets at DX (Revised: 11/19/2009)

Code	Description	TNM 7	TNM 6	SS77	SS2000
00	No; none	NA	NA	NONE	NONE
10	Distant lymph node(s), NOS	NA	NA	D	D
40	Distant metastases except distant lymph node(s) (code 10) Carcinomatosis	NA	NA	D	D
50	40 + 10 Other distant metastases plus distant lymph node(s)	NA	NA	D	D
60	Distant metastasis, NOS	NA	NA	D	D
99	Unknown if distant metastasis Distant metastasis cannot be assessed Not documented in patient record	NA	NA	U	U

Intracranial Gland

CS Mets Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Intracranial Gland

CS Site-Specific Factor 1 WHO Grade Classification (Revised: 12/10/2009)

Note: Code the WHO Grade Classification as documented in the medical record.

Code	Description
010	Grade I

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
020	Grade II
030	Grade III
040	Grade IV
999	Clinically diagnosed/grade unknown Not documented in medical record Grade unknown, NOS

Intracranial Gland

CS Site-Specific Factor 2 Proliferative Fraction- Ki-67/MIB-1 (Revised: 12/23/2009)

Note 1: Ki-67 and MIB-1 are labeling indexes used as a complementary method to differentiate better and worse prognostic groups of certain brain tumors. They evaluate the cell kinetics in brain tumors. Code the labeling index fraction percentage using Ki-67 or MIB-1 (monoclonal antibody) when it is available on the final diagnosis of the pathology report of the primary brain tumor.

Note 2: Record the Labeling Index (LI) percentage as documented by the pathologist as an exact number (001-100). For instance, if the LI level is recorded by the pathologist as 15%, assign code 015. If percentage is documented as 13.7% round up to 14% and assign code 014. If percentage is documented as 13.2%, round down to 13% and assign code 013.

Code	Description
001-100	1-100% (code exact Labeling Index percentage) Examples: 001 = 1% 010 = 10% 014 = 13.7% 055 = 55.2%
200	Labeling Index normal
300	Labeling Index stated as slightly elevated and no percentage provided
400	Labeling Index stated as elevated and no percentage provided
888	OBSOLETE DATA CONVERTED V0200 See code 988. Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Intracranial Gland

CS Site-Specific Factor 3 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 4 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 5 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 6 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 7 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Intracranial Gland

CS Site-Specific Factor 8 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 9 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 10 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 11 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 12 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 13 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 14 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Intracranial Gland

CS Site-Specific Factor 15 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 16 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 17 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 18 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 19 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 20 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 21 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Intracranial Gland

CS Site-Specific Factor 22 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 23 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 24 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Intracranial Gland

CS Site-Specific Factor 25 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema